Wire flash
Eli Lilly Raises 2026 Sales Guidance to $91B-$92B as Q3 Revenue Beats Estimates
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Eli Lilly (LLY.N) reported third-quarter 2026 revenue of $24.4 billion, beating Wall Street's average estimate of $22.5 billion, and raised its full-year sales guidance to $91-92 billion from a prior range of $85-87 billion. The company attributed a slightly lower adjusted EPS outlook of $35-36 to acquisition impacts. Diabetes drug Mounjaro posted $10.7 billion in sales and weight-loss drug Zepbound $5.35 billion, both exceeding analyst expectations. Lilly shares rose over 4% premarket and are up nearly 20% year-to-date as of Wednesday's close, extending its lead in the weight-loss drug market.
Source report
October 29 — Eli Lilly (LLY.N) released its third-quarter 2026 earnings report, raising its full-year sales guidance and providing updates on regulatory approvals for its products.
Updated Guidance
- The company now expects full-year 2026 sales of $91 billion to $92 billion, up from its previous forecast of $85 billion to $87 billion.
- Due to the impact of acquisitions, the company expects full-year adjusted earnings per share of $35 to $36, slightly below its previous guidance range.
Third-Quarter Results
- Quarterly revenue reached $24.4 billion, beating the Wall Street analyst average estimate of $22.5 billion.
- Diabetes drug Mounjaro posted sales of $10.7 billion.
- Weight-loss drug Zepbound posted sales of $5.35 billion.
- Both products exceeded analyst expectations.
Market Reaction
- Eli Lilly shares rose more than 4% in premarket trading.
- As of Wednesday's close, the stock had gained nearly 20% year to date.
Source
domesticNeutral / independent